Safety of Racotumomab in the treatment of patients with non-small cell lung cancer
Abstract
In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary to identify new therapeutical options. Immunological approaches are interesting because of the potential activity without the toxicities of conventional chemotherapy. The Center of Molecular Immunology developed a vaccine called Racotumomab; it acts on the lung carcinoma inducing an increase in tumor apoptosis and a decrease in the number of tumor vessels. A expanded access, multicenter, open study was conducted in 86 patients with non-small cell lung cancer in order to assess its safety. The administered dose was 1 mg/mL intradermically. The first 5 doses were administered every 14 days and the remaining 10 every 28 days until completing the treatment. The follow-up re immunizations were every 28 days. The occurrence of adverse events (AE) was analyzed and they were classified according to CTC v4.02 criteria. Adverse events were reported by 58 patients (67.4%), making a total of 215 events. burning at the injection site was the most frequently reported event, 32 (14.9%). The use of the vaccine in the patients under study showed good safety and tolerance.References
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
Ministerio de Salud Pública, Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2010. La Habana: MINSAP; 2011.
Neninger E, Díaz R, de la Torre A, Rives R, Díaz A, Suárez G, et al. Active immunotherapy with 1E10 MAb anti-idiotype vaccine in patients with small cell lung cancer. Report of a phase I trial. Cancer Biol Ther 2007;6:145-50.
Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, et al. An antiIdiotype vaccine elicits a specific response to N-Glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168:2523-9.
Hernández AM, Rodríguez M, López-Requena A, Beausoleil I, Pérez R, Vázquez AM, et al. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self-versus non-self-matter. Immunobiology 2005;210(1):11-21.
Vázquez AM, Gabri M, Hernández AM, Alonso DF, Beausoleil I, Gómez DE, et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 2000;7:751-6.
Díaz A, Alfonso M, Alonso R, Suárez G, Troche M, Catalá M. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003;107(2):80-9.
Alfonso S, Díaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, et al. 1E10 Anti-idiotype Vaccine in Non-Small Cell Lung Cancer. Experience in Stage IIIb/IV Patients. Cancer Biol Ther 2007;6:1847-52.
U.S Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Washington: National Institutes of Health-National Cancer Institute; 2009.
Schiller JH, Harrington D, Belani CP, Sandler A, Langer C, Sandler A, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
Carr A, Rodríguez E, Arango MC, Camacho R, Osorio M, Gabri M, et al, Immunotherapy of Advanced Breast Cancer With a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine. J Clin Oncol 2003;21:1015-21.
Toledo D, Alfonso S, Santiesteban E, Aguirre F, Hernández AM, Mazorra Z, et al. La Vacuna Anti-idiotipo 1E10: Experiencias en la Inmunoterapia del Cáncer Avanzado. Cancerología 2009:4(3):143-6.
VacciMonitor is an open Journal under Creative Commons License. The journal allows reuse and remixing of its content in accordance with: https://creativecommons.org/licenses/by-nc/4.0/, and the authors retain their copyright.
-Authors can distribute electronic or print copies of the published article among students or colleagues, including the authorization to be used for educational purposes by other specialists of the institution.
-Re-use the whole article or a part of it in new manuscripts or future books.
-Authors are authorized by VacciMonitor to use either their version or the one edited by the Journal in their personal website or in any other free-access repository.
-VacciMonitor authorizes other publishing houses or databases to reproduce the published original materials if the journal source is mentioned.
